GCCL Signs MOU with Seoul National University’s Research Center for Neuro-Psychiatric Disorder to Strengthen Collaboration in Clinical Research

▶ Strategic partnership to advance clinical research in neuropsychiatric disorders, expand domestic and international infrastructure, and enhance global competitiveness

Global clinical trial sample analysis organization GCCL (Global Clinical Central Lab, CEO KwanGoo Cho) announced on September 22 that it signed a Memorandum of Understanding (MOU) on September 19 with the Research Center for Neuro-Psychiatric Disorder of Seoul National University (CLEVERcns, Director Ki-Jeong Cheon) to promote mutual collaboration in clinical research on neuropsychiatric disorders and contribute to the development of the pharmaceutical industry.

The MOU signing ceremony was attended by key representatives from both organizations, including CEO Kwan-Gu Cho of GCCL and Director Ki-Jeong Cheon of CLEVERcns. The parties reaffirmed their commitment to enhancing the quality of domestic neuropsychiatric clinical trials, expanding infrastructure for CNS clinical trial sample analysis, and strengthening global competitiveness.

Key areas of collaboration outlined in the MOU include: ▲ Strengthening preclinical-to-clinical linkages in brain disease research, ▲ Joint development of CNS disease biomarkers and analytical methods, ▲ Collaborative operation of educational programs and exchange of technical and academic information, ▲ Joint promotion and support for “end-to-end CNS projects” and cooperation in global expansion, ▲ Sharing and utilization of domestic and international networks, infrastructure, and resources, ▲ Other areas of mutual interest as needed.

CLEVERcns, a Seoul National University Hospital-affiliated center, leverages the hospital’s and university’s facilities and research infrastructure to support new drug development in neuropsychiatric disorders, providing clinical consultation and efficacy evaluation services. GCCL provides comprehensive clinical trial sample analysis services for the field and is a leader in developing CNS disease biomarkers and analytical methods.

Through this collaboration, GCCL and CLEVERcns aim to generate more precise and reliable research data while providing end-to-end support from preclinical to clinical research for brain and CNS disorder studies.

Director Ki-Jeong Cheon of CLEVERcns stated, “Research in neuropsychiatric disorders is highly complex and challenging, and obtaining high-quality clinical trial data is critical to the success of drug development. Through this MOU, domestic pharmaceutical and biotech companies, as well as researchers, will be able to utilize a world-class CNS clinical research environment more efficiently, contributing to the global recognition of Korea’s CNS research capabilities.”

CEO KwanGoo Cho of GCCL added, “GCCL supports clinical trial success for domestic and international pharmaceutical and biotech companies by providing state-of-the-art analytical platforms and high-quality analytical services in CNS research. Our strategic collaboration with CLEVERcns represents an important step in strengthening the overall CNS research ecosystem. We will continue to prioritize data reliability and analytical quality while offering differentiated clinical trial sample analysis services in the global market.”

GCCL is a fully GCLP-certified (Good Clinical Laboratory Practice) clinical trial sample analysis organization in Korea, providing tailored clinical analysis services that meet global standards across all phases of clinical trials, from Phase 1 to Phase 4. With advanced analytical platforms, including ddPCR instruments, and specialized sample analysis and method development services, GCCL supports domestic pharmaceutical and biotech companies as well as partners throughout Asia and worldwide.